Genmab A/S (NASDAQ:GMAB) Rating Reiterated by Truist Financial

Genmab A/S (NASDAQ:GMAB)‘s stock had its “buy” rating reaffirmed by equities research analysts at Truist Financial in a report issued on Tuesday, Benzinga reports. They currently have a $50.00 price objective on the stock. Truist Financial’s target price suggests a potential upside of 63.24% from the company’s current price.

Several other analysts have also issued reports on GMAB. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Wednesday, March 6th. Citigroup cut Genmab A/S from a “neutral” rating to a “sell” rating in a research report on Monday, January 22nd. BMO Capital Markets upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $46.00 to $48.00 in a research note on Friday, February 23rd. Finally, UBS Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, December 6th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $48.50.

Genmab A/S Price Performance

NASDAQ GMAB opened at $30.63 on Tuesday. The stock has a market capitalization of $20.24 billion, a price-to-earnings ratio of 31.91, a PEG ratio of 1.40 and a beta of 0.98. Genmab A/S has a 1-year low of $26.32 and a 1-year high of $42.99. The business’s fifty day moving average price is $28.85 and its 200-day moving average price is $31.10.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.02. The company had revenue of $675.29 million during the quarter, compared to analysts’ expectations of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. Equities research analysts anticipate that Genmab A/S will post 1.09 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

Hedge funds and other institutional investors have recently made changes to their positions in the company. Keybank National Association OH purchased a new position in shares of Genmab A/S during the 3rd quarter worth about $1,154,000. Knights of Columbus Asset Advisors LLC lifted its stake in shares of Genmab A/S by 16.8% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 5,712 shares of the company’s stock worth $201,000 after acquiring an additional 822 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Genmab A/S by 20.9% during the 2nd quarter. Franklin Resources Inc. now owns 645,637 shares of the company’s stock worth $24,541,000 after acquiring an additional 111,451 shares during the last quarter. Northern Trust Corp boosted its holdings in Genmab A/S by 83.3% during the 3rd quarter. Northern Trust Corp now owns 559,044 shares of the company’s stock valued at $19,717,000 after acquiring an additional 254,042 shares during the period. Finally, HBK Sorce Advisory LLC grew its position in Genmab A/S by 4.8% in the 3rd quarter. HBK Sorce Advisory LLC now owns 9,139 shares of the company’s stock valued at $322,000 after acquiring an additional 419 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.